Matches in Wikidata for { <http://www.wikidata.org/entity/Q91104993> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q91104993 description "artículu científicu espublizáu en xineru de 2019" @default.
- Q91104993 description "scientific article published on 17 January 2019" @default.
- Q91104993 description "wetenschappelijk artikel" @default.
- Q91104993 description "наукова стаття, опублікована 17 січня 2019" @default.
- Q91104993 name "Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study" @default.
- Q91104993 name "Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study" @default.
- Q91104993 type Item @default.
- Q91104993 label "Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study" @default.
- Q91104993 label "Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study" @default.
- Q91104993 prefLabel "Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study" @default.
- Q91104993 prefLabel "Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study" @default.
- Q91104993 P1433 Q91104993-274A91E2-B293-44A8-AC3D-76542697C709 @default.
- Q91104993 P1476 Q91104993-A0F35904-D2C8-4F51-BF61-1CA4A5574728 @default.
- Q91104993 P2093 Q91104993-1E251282-FF5A-4A69-B457-F065E13482B0 @default.
- Q91104993 P2093 Q91104993-6580D916-F7C3-4C7E-AC11-9A08003C3DB2 @default.
- Q91104993 P2093 Q91104993-6D3792FD-F95B-430A-8B58-0B16D5543B42 @default.
- Q91104993 P2093 Q91104993-8580DEAE-91EB-4865-A2CC-B8D083DD970D @default.
- Q91104993 P2093 Q91104993-90A9C6D9-C486-41EA-930F-E51698D035F6 @default.
- Q91104993 P2093 Q91104993-E09C36CC-69D4-4D67-ABD8-BF94F175D73B @default.
- Q91104993 P304 Q91104993-1EF687B8-D007-442B-A0C1-A92E7FB603DA @default.
- Q91104993 P31 Q91104993-C5B3F943-4C1B-4900-80EB-842F5AD666D0 @default.
- Q91104993 P356 Q91104993-1F3C5426-924C-4B2D-B27F-9DF365267695 @default.
- Q91104993 P433 Q91104993-8C748324-C10A-4415-8862-2F8A4005B61A @default.
- Q91104993 P478 Q91104993-E0AFDF36-85A7-42B6-8768-03E1F71937AC @default.
- Q91104993 P50 Q91104993-F0039A92-C4F4-4760-A61F-A87A072B9A60 @default.
- Q91104993 P577 Q91104993-9CCE9333-3D9A-4D9C-AB82-9891A7469004 @default.
- Q91104993 P698 Q91104993-5FAB31D0-324D-47B3-A024-F45957D2B4B7 @default.
- Q91104993 P921 Q91104993-057BD49E-C448-4A88-870B-B86F97B05DAE @default.
- Q91104993 P356 BJH.15760 @default.
- Q91104993 P698 30656671 @default.
- Q91104993 P1433 Q4970200 @default.
- Q91104993 P1476 "Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study" @default.
- Q91104993 P2093 "Ana García-Noblejas" @default.
- Q91104993 P2093 "Concepción Alaez Uson" @default.
- Q91104993 P2093 "Concepción Nicolás" @default.
- Q91104993 P2093 "Javier López-Jiménez" @default.
- Q91104993 P2093 "María José Requena" @default.
- Q91104993 P2093 "Reyes Arranz" @default.
- Q91104993 P304 "168-170" @default.
- Q91104993 P31 Q13442814 @default.
- Q91104993 P356 "10.1111/BJH.15760" @default.
- Q91104993 P433 "1" @default.
- Q91104993 P478 "186" @default.
- Q91104993 P50 Q91104990 @default.
- Q91104993 P577 "2019-01-17T00:00:00Z" @default.
- Q91104993 P698 "30656671" @default.
- Q91104993 P921 Q412323 @default.